ANRO - Alto Neuroscience, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ANRO

ALTO NEUROSCIENCE, INC.

NYSE

$24.37

▲ UP 1.41% (0.34)

KEY STATISTICS

Market Cap$843.66 M

52w High$37.48

52w Low$5.22

Dividend Yield—

Frequency—

P/E-10.07

Volume649.43K

Shares Out.35.09M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Amit Etkin

COMPENSATION 2026

Salary$650,671

Stock Awards$0

Incentive Plan Pay$358,072

All Other Comp.$25,558

Total$2,188,487

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 2, 2024

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$55.00

Target Low$24.00

Target Median$36.50

Target Consensus$38.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

100

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

47.58%

HOLDERS

127

TOP 8 OF 127 · RANKED BY POSITION SIZE

Alpha Wave Global, LP

Vestal Point Capital, LP

2.5M sh

$44.23M

Perceptive Advisors LLC

2.0M sh

$45.18M

Armistice Capital, LLC

1.6M sh

$6.58M

Point72 Asset Management, L.P.

Franklin Resources Inc

1.2M sh

$4.67M

PRICE

$24.37 ▲ UP 1.41% (+$0.34)

About Alto Neuroscience, Inc.

https://www.altoneuroscience.com ↗

Alto Neuroscience, Inc., a Los Altos-based clinical-stage biopharma, develops innovative drugs for MDD, PTSD, and schizophrenia, utilizing AI-driven biomarkers and novel compounds like ALTO-100, ALTO-300, ALTO-101, ALTO-202, and ALTO-203.

INDUSTRY

Biotechnology

A PRODUCT ALTO NEUROSCIENCE, INC. IS KNOWN FOR

ALTO-300

An oral small molecule in Phase 2b trials for MDD, developed as an adjunctive treatment for patients identified by EEG biomarkers, with positive interim results and full topline data expected in mid-2026.

COMPETITORS

COMPETITOR

AXSM COMPARE

CMPS COMPARE

RLMD COMPARE

Alto Neuroscience in 2025

SENTIMENT: + POSITIVE

REGULATORY · OCTOBER 2025

Alto Neuroscience Stock Soars Over 80% After Favorable FDA Meeting for Depression Drug and Announcement of $50 Million Financing

On October 20, 2025, Alto Neuroscience announced a successful meeting with the U.S. Food and Drug Administration (FDA) that cleared an accelerated development path for its treatment-resistant depression drug, ALTO-207. Concurrently, the company announced a $50 million private placement financing led by Perceptive Advisors, with participation from other biotechnology investors. This dual announcement significantly boosted investor confidence, leading to a dramatic single-day stock price surge.

PRODUCT STRATEGY · OCTOBER 2025 · IN PROGRESS

Alto Neuroscience Accelerates Development of ALTO-207 for Treatment-Resistant Depression Following Successful FDA Meeting and Secures $50 Million in Financing

In a significant strategic move, Alto Neuroscience announced plans to accelerate the development of its drug candidate ALTO-207 for treatment-resistant depression after a successful meeting with the FDA. To support this expedited timeline, the company secured approximately $50 million through a private placement financing (PIPE).